Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | NT5E | P21589 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131219 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL8373455 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL15472807 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL7753712 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL489384 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL20128456 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL24652562 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL278439 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL22826758 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL6725298 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430647-A | Preparation method of regadenoson | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-110483602-B | Preparation method of regadenoson | 常州方圆制药有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-110483602-A | A kind of preparation method of Rui Jiadesong | CHANGZHOU FANG YUAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | claimed |
| US-RE47301-E1 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | GILEAD SCIENCES, INC. (US) | 2019-03-19 | — | — | US | claimed |
| US-9085601-B2 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | GILEAD SCIENCES, INC. (US) | 2015-07-21 | — | — | US | claimed |
| US-20140213539-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | GILEAD SCIENCES, INC. (US) | 2014-07-31 | — | — | US | claimed |
| US-20140206857-A1 | METHOD FOR THE PREPARATION OF 2-(4-METHOXYCARBONYLPYRAZOL-1-YL)ADENOSINE AND 2-(4-ETHOXYCARBONYLPYRAZOL-1-YL)ADENOSINE | FARMAK, A.S. (CZ) | 2014-07-24 | — | — | US | claimed |
| US-8524883-B2 | Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | claimed |
| WO-2013023626-A1 | A METHOD FOR THE PREPARATION OF 2-(4-METHOXYCARBONYLPYRAZOL-L-YL)ADENOSINE AND 2-(4-ETHOXYCARBONYLPYRAZOL-L-YL)ADENOSINE | FARMAK, A.S. (CZ) | 2013-02-21 | — | — | WO | claimed |
| WO-2012149196-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF REGADENOSON AND A NEW CRYSTALLINE FORM THEREOF | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-11-01 | — | — | WO | claimed |
| US-20120165350-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | GILEAD SCIENCES, INC. | 2012-06-28 | — | — | US | claimed |
| EP-0567094-B1 | Hydrazoadenosines | DISCOVERY THERAPEUTICS INC (US) | 1999-03-03 | — | — | EP | claimed |
| CN-114096551-B | With A2A2-Benzylidene hydrazino adenosines with adenosine receptor agonistic activity | 中国人民解放军军事科学院军事医学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-113943334-B | A, A 2A Process for preparing adenosine receptor agonists | 常州方圆制药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114249785-B | Preparation method of 2-adenosine N-pyrazole derivative regadenoson | 常州方圆制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117430647-A | Preparation method of regadenoson | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-1995007049-A1 | DIAGNOSTIC USES OF HYDRAZINOADENOSINES | DISCOVERY THERAPEUTICS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| WO-1994006438-A1 | ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5278150-A | Vasodilation | WHITBY RESEARCH, INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0567094-A2 | Hydrazoadenosines | Discovery Therapeutics, Inc. (US) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206857-A1 | METHOD FOR THE PREPARATION OF 2-(4-METHOXYCARBONYLPYRAZOL-1-YL)ADENOSINE AND 2-(4-ETHOXYCARBONYLPYRAZOL-1-YL)ADENOSINE | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885CYP1A2 278/4885 |
| US-20120165350-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885CYP1A2 161/4885 |
| US-20140213539-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885CYP1A2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.